STADA licenses teriparatide and further expands biosimilar portfolio

14.10.2014 10:14

STADA Arzneimittel AG is licensing teriparatide and is once again expanding its biosimilar portfolio. The teriparatide biosimilar is being developed by Richter-Helm BioTec GmbH & Co. KG and is to be introduced across Europe under the STADA label after the patent expiry of the original preparation Forsteo.

“With this further in-licensing, we are consistently pursuing our biosimilar strategy, in which we rely on cooperation with highly specialized partners in order to expand our portfolio with high-quality preparations at favorable conditions,” explains STADA CEO Hartmut Retzlaff.

According to the terms of the contract, STADA is obliged to make further payments depending on the progress of the project in addition to a payment upon signing the contract. Once marketing begins, STADA will report the resulting sales and make license payments to Richter-Helm.

“With the teriparatide biosimilar from STADA, the therapy spectrum for osteoporosis patients is expanded to include a qualitatively absolutely equivalent but cheaper alternative with proven therapeutic equivalence to the first-party product,” says Dr. Michael Mack, Vice President Biotechnology at STADA is convinced.

STADA is expected to bring teriparatide onto the market in 2019, thereby adding another active ingredient to its existing biosimilar offering. The STADA sales company cell pharm has been selling SILAPO with the active ingredient epoetin zeta since 2008. This year, its wholly owned subsidiary cell pharm also introduced the filgrastim product Grastofil.